Back to top
more

Quanterix (QTRX)

(Delayed Data from NSDQ)

$17.35 USD

17.35
297,152

-0.53 (-2.96%)

Updated May 16, 2024 04:00 PM ET

After-Market: $17.34 -0.01 (-0.06%) 7:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (143 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Thermo Fisher (TMO) Expands Capabilities in St. Louis Facility

by Zacks Equity Research

Thermo Fisher (TMO) expands manufacturing capacity at the St. Louis site for Biologics treatment.

Here's Why You Should Buy Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors are optimistic about Globus Medical (GMED) on growing musculoskeletal devices demand and strong industry prospects.

LabCorp (LH) to Expand Diagnostics Services With New Deal

by Zacks Equity Research

LabCorp's (LH) recent deal will bring together critical expertise, experience and technology from both organizations to improve the delivery of high-quality patient care.

QIAGEN (QGEN) Broadens QuantiFERON Line With EBV RUO Assay

by Zacks Equity Research

QIAGEN (QGEN) notes that T-cells are vital in combatting viral infections and the QuantiFERON-EBV RUO assay focuses on measuring the T-cell response to EBV.

Bruker (BRKR) Becomes Majority Investor in MIRO Analytical AG

by Zacks Equity Research

Bruker's (BRKR) majority investment in MIRO adds state-of-the-art QCL technology to the Bruker Optics gas-analysis portfolio.

Here's Why Investors Should Retain Integra (IART) Stock Now

by Zacks Equity Research

International expansion and the strong prospects of the CSS segment bode well for Integra (IART).

Here's Why You Should Invest in Neogen (NEOG) Stock Now

by Zacks Equity Research

Investors are optimistic about Neogen (NEOG), led by progress in the Food Safety business and recent product launches.

Medtronic (MDT) to Launch Academic R&D Grants With New Pact

by Zacks Equity Research

Medtronic's (MDT) partnership will enable teachers to improve their skill set, boosting student opportunities to pursue STEM careers in corporate America.

Penumbra (PEN) Rides on New Product Offerings as FX Woe Ails

by Zacks Equity Research

Penumbra (PEN) sees an acceleration of Lightning Bolt 7 cases as conversion from surgery, lytics and other mechanical thrombectomy products gains momentum.

Bruker (BRKR) Introduces the New Hysitron TI 990 TriboIndenter

by Zacks Equity Research

Bruker's (BRKR) TI 990 is a comprehensive advancement of its industry-leading TriboIndenter platform.

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC), backed by the strength of the dental business and acquisitions.

Exact Sciences (EXAS) Aided by Innovation, Strategic Buyouts

by Zacks Equity Research

Exact Sciences (EXAS) is planning several key milestones to bring six innovative cancer diagnostics from its pipeline to patients in need.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about ResMed (RMD) due to the core business' performance and sustained growth in the SaaS business.

Here's Why You Should Retain CVS Health (CVS) Stock for Now

by Zacks Equity Research

Investors continue to remain optimistic about CVS Health (CVS) due to the new acquisitions and the strong execution of the pharmacy business.

Zimmer Biomet (ZBH) Gains From ROSA Sales Growth Amid FX Woes

by Zacks Equity Research

Zimmer Biomet (ZBH) plans to work on the overall shift of the company's legacy knee systems to a fully rounded-out Persona portfolio.

Abbott (ABT) Rides on Nutrition Recovery Amid Low Testing Sales

by Zacks Equity Research

Abbott's (ABT) Nutrition business has started showing signs of recovery since the beginning of 2023.

Quanterix Corporation (QTRX) Moves 7.2% Higher: Will This Strength Last?

by Zacks Equity Research

Quanterix Corporation (QTRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Here's Why You Should Retain Hologic (HOLX) Stock for Now

by Zacks Equity Research

Investors continue to remain optimistic about Hologic (HOLX), backed by the Breast Health business' performance and international execution.

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

by Zacks Equity Research

Investors are increasingly optimistic about Labcorp (LH) due to its progress in hospital partnerships.

Neogen (NEOG) Gains From Strong Segmental Sales, Innovation

by Zacks Equity Research

Within the biosecurity portfolio, Neogen (NEOG) continues to record solid growth in cleaners, disinfectants and rodenticides.

Here's Why Investors Should Retain STERIS (STE) Stock for Now

by Zacks Equity Research

STERIS' (STE) healthcare segment benefits from procedure recovery, boosting investors' optimism.

Here's Why You Should Buy Align Technology (ALGN) Stock Now

by Zacks Equity Research

The rapid expansion of Align Technology's (ALGN) business in international markets remains a key growth driver.

Henry Schein (HSIC) Gains From Strong Global Network Amid FX Woes

by Zacks Equity Research

Henry Schein's (HSIC) dental software business is progressing well despite a challenging business environment.

Terumo's (TRUMY) MicroVention Enters Transradial Access Space

by Zacks Equity Research

The SOFIA EX 5F Catheter by Terumo's (TRUMY) MicroVention boasts a new design to enhance trackability.

Charles River (CRL) Opens a RightSource Lab in Stevenage

by Zacks Equity Research

Charles River's (CRL) new RightSource facility is likely to provide services to the Stevenage advanced therapy biocluster.